ORTHOPEDIATRICS CORP(KIDS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,223 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
KIDS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ORTHOPEDIATRICS CORP (KIDS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KIDS at 37.8/100 on a 32-signal composite quality model, placing it at rank #2,223 of 2,962 stocks — the bottom half of the AI-ranked universe. KIDS scores in the top quartile across revenue growth (79.3). Areas of concern include balance sheet strength (19.1) and profitability (19.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ORTHOPEDIATRICS CORP reports quarterly revenue of $70.5M, net income of $-7.2M, free cash flow of $-3.1M. Top institutional holders of KIDS by reported 13-F value include BROWN ADVISORY, BlackRock, BRAIDWELL, based on the most recent SEC filings. KIDS trades on the Nasdaq exchange and files with the SEC under CIK 1425450. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KIDS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORTHOPEDIATRICS CORP directly from SEC EDGAR. ORTHOPEDIATRICS CORP's 13F Pro composite quality score has ranged between 26 and 44 since 2021, currently 37.8 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$70.5M
Net Income
Q2 2026
$-7.2M
Free Cash Flow
Q2 2026
$-3.1M
ROIC
Q2 2026
-3.6%
D/E Ratio
Q2 2026
0.32
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+15.4% YoYNet Income
-4.8% YoYOperating Income
-12.1% YoYEPS (Diluted)
-3.0% YoYTotal Assets
+7.5% YoYTotal Debt
+37.6% YoYOp. Cash Flow
+82.1% YoYFree Cash Flow
+61.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $236.3M +15.4% | $204.7M +37.6% | $148.7M +21.6% | $122.3M +24.7% | $98.0M +37.9% | $71.1M |
| Net Income | $-39.6M -4.8% | $-37.8M -80.3% | $-21.0M -1767.2% | $1.3M +107.7% | $-16.3M +50.6% | $-32.9M |
| Operating Income | $-39.2M -12.1% | $-35.0M -30.9% | $-26.8M -5.3% | $-25.4M -40.9% | $-18.0M +32.6% | $-26.8M |
| EPS (Diluted) | $-1.69 -3.0% | $-1.64 -78.3% | $-0.92 -1633.3% | $0.06 +107.1% | $-0.84 +53.8% | $-1.82 |
| Total Assets | $508.6M +7.5% | $473.2M +7.9% | $438.7M +2.6% | $427.7M +40.6% | $304.3M -5.0% | $320.4M |
| Total Debt | $107.9M +37.6% | $78.4M +598.9% | $11.2M +967.1% | $1.1M -11.0% | $1.2M -9.6% | $1.3M |
| Operating Cash Flow | $-4.9M +82.1% | $-27.0M -0.0% | $-27.0M -24.3% | $-21.8M -66.6% | $-13.1M +29.5% | $-18.5M |
| Free Cash Flow | $-16.0M +61.4% | $-41.3M +5.9% | $-43.9M -38.1% | $-31.8M -50.2% | $-21.2M +27.1% | $-29.0M |
Get alerted when KIDS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ORTHOPEDIATRICS CORP including:
Top Institutional Holders of KIDS
BROWN ADVISORY INC
$32.1M1,678,983 shBlackRock, Inc.
$24.3M1,272,714 shBRAIDWELL LP
$21.1M1,100,370 shGranahan Investment Management, LLC
$20.8M1,085,964 shMILLENNIUM MANAGEMENT LLC
$15.6M816,830 shWELLINGTON MANAGEMENT GROUP LLP
$15.2M794,309 shVANGUARD CAPITAL MANAGEMENT LLC
$14.5M755,624 shSoleus Capital Management, L.P.
$14.0M732,144 shMORGAN STANLEY
$13.3M693,387 shWASATCH ADVISORS LP
$9.9M515,677 sh
| Fund | Value | Shares |
|---|---|---|
| BROWN ADVISORY INC | $32.1M | 1,678,983 |
| BlackRock, Inc. | $24.3M | 1,272,714 |
| BRAIDWELL LP | $21.1M | 1,100,370 |
| Granahan Investment Management, LLC | $20.8M | 1,085,964 |
| MILLENNIUM MANAGEMENT LLC | $15.6M | 816,830 |
| WELLINGTON MANAGEMENT GROUP LLP | $15.2M | 794,309 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.5M | 755,624 |
| Soleus Capital Management, L.P. | $14.0M | 732,144 |
| MORGAN STANLEY | $13.3M | 693,387 |
| WASATCH ADVISORS LP | $9.9M | 515,677 |
Companies Similar to KIDS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Cryoport, Inc.
ADC Therapeutics SA
FENNEC PHARMACEUTICALS INC.
CASTLE BIOSCIENCES INC
Evolus, Inc.
BIODESIX INC
Alpha Teknova, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KIDS on your watchlist
Track score changes the day ORTHOPEDIATRICS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KIDS a good stock to buy?
13F Pro's AI-powered analysis of ORTHOPEDIATRICS CORP (KIDS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KIDS are available on the KIDS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KIDS is classified as a small company.
Which hedge funds own KIDS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KIDS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ORTHOPEDIATRICS CORP's investment landscape.